| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emphysema | 12 | 2024 | 68 | 5.070 |
Why?
|
| Lung | 43 | 2025 | 1508 | 4.710 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 23 | 2025 | 608 | 4.520 |
Why?
|
| Pulmonary Emphysema | 12 | 2024 | 93 | 3.960 |
Why?
|
| Cigarette Smoking | 8 | 2025 | 59 | 2.810 |
Why?
|
| Th17 Cells | 10 | 2024 | 91 | 2.560 |
Why?
|
| Smoking | 17 | 2020 | 1050 | 2.470 |
Why?
|
| Asthma | 25 | 2019 | 762 | 2.240 |
Why?
|
| Lung Neoplasms | 11 | 2025 | 1668 | 2.030 |
Why?
|
| Electronic Nicotine Delivery Systems | 4 | 2022 | 53 | 1.700 |
Why?
|
| Immunity, Innate | 14 | 2023 | 375 | 1.660 |
Why?
|
| Smoke | 11 | 2025 | 61 | 1.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2025 | 355 | 1.580 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2025 | 59 | 1.550 |
Why?
|
| Influenza A virus | 2 | 2025 | 139 | 1.390 |
Why?
|
| Soot | 3 | 2022 | 15 | 1.330 |
Why?
|
| Interleukin-17 | 6 | 2024 | 122 | 1.270 |
Why?
|
| Matrix Metalloproteinase 2 | 9 | 2011 | 95 | 1.240 |
Why?
|
| Lung Diseases | 7 | 2018 | 390 | 1.230 |
Why?
|
| Antigen-Presenting Cells | 6 | 2019 | 118 | 1.230 |
Why?
|
| Th2 Cells | 21 | 2021 | 186 | 1.210 |
Why?
|
| Mice | 65 | 2025 | 17864 | 1.180 |
Why?
|
| Animals | 86 | 2025 | 34519 | 1.140 |
Why?
|
| Autoimmunity | 5 | 2019 | 173 | 1.080 |
Why?
|
| Hypersensitivity | 12 | 2022 | 187 | 1.060 |
Why?
|
| DNA Cleavage | 2 | 2017 | 6 | 1.040 |
Why?
|
| Dendritic Cells | 9 | 2023 | 417 | 1.040 |
Why?
|
| Peptide Hydrolases | 12 | 2019 | 146 | 1.010 |
Why?
|
| T-Lymphocytes | 6 | 2020 | 1721 | 0.990 |
Why?
|
| Macrophages, Alveolar | 6 | 2025 | 49 | 0.980 |
Why?
|
| Disease Models, Animal | 27 | 2025 | 4466 | 0.980 |
Why?
|
| Cytokines | 14 | 2023 | 1304 | 0.960 |
Why?
|
| Mycoses | 9 | 2023 | 117 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 29 | 2025 | 4463 | 0.950 |
Why?
|
| Neuraminidase | 1 | 2025 | 36 | 0.930 |
Why?
|
| Plasma Cells | 1 | 2025 | 55 | 0.920 |
Why?
|
| Antigens, Neoplasm | 2 | 2025 | 384 | 0.910 |
Why?
|
| Allergens | 15 | 2018 | 257 | 0.910 |
Why?
|
| Matrix Metalloproteinases | 3 | 2017 | 67 | 0.870 |
Why?
|
| Matrix Metalloproteinase 9 | 9 | 2019 | 140 | 0.860 |
Why?
|
| Inflammation | 12 | 2023 | 1462 | 0.810 |
Why?
|
| Respiratory Hypersensitivity | 8 | 2019 | 52 | 0.790 |
Why?
|
| Elastin | 2 | 2019 | 31 | 0.790 |
Why?
|
| Pulmonary Alveoli | 8 | 2021 | 136 | 0.780 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 771 | 0.780 |
Why?
|
| Th1 Cells | 5 | 2012 | 153 | 0.760 |
Why?
|
| Mice, Knockout | 23 | 2020 | 3775 | 0.750 |
Why?
|
| Respiratory Mucosa | 7 | 2021 | 92 | 0.740 |
Why?
|
| Lymphocyte Activation | 9 | 2021 | 700 | 0.730 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2019 | 474 | 0.720 |
Why?
|
| Humans | 101 | 2025 | 126285 | 0.720 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 685 | 0.710 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 123 | 0.710 |
Why?
|
| Influenza, Human | 2 | 2025 | 666 | 0.670 |
Why?
|
| Complement C1q | 1 | 2019 | 19 | 0.630 |
Why?
|
| Tobacco Products | 4 | 2020 | 61 | 0.600 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2018 | 158 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 29 | 0.570 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 1029 | 0.560 |
Why?
|
| Respiratory Function Tests | 2 | 2024 | 202 | 0.560 |
Why?
|
| Adaptive Immunity | 4 | 2022 | 90 | 0.560 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2021 | 81 | 0.550 |
Why?
|
| Pneumonia | 6 | 2022 | 325 | 0.550 |
Why?
|
| Disease Progression | 9 | 2024 | 2103 | 0.540 |
Why?
|
| Wound Healing | 3 | 2017 | 467 | 0.530 |
Why?
|
| Fibrinogen | 5 | 2019 | 157 | 0.530 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 356 | 0.530 |
Why?
|
| Aspergillus niger | 6 | 2021 | 20 | 0.530 |
Why?
|
| Toll-Like Receptor 4 | 6 | 2023 | 138 | 0.520 |
Why?
|
| Vaping | 3 | 2022 | 30 | 0.510 |
Why?
|
| Peripheral Tolerance | 1 | 2015 | 4 | 0.500 |
Why?
|
| Osteopontin | 2 | 2014 | 50 | 0.480 |
Why?
|
| Receptors, Complement | 2 | 2014 | 32 | 0.480 |
Why?
|
| Glycosphingolipids | 1 | 2015 | 11 | 0.470 |
Why?
|
| Nanoparticles | 2 | 2015 | 254 | 0.470 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 338 | 0.460 |
Why?
|
| Epoxide Hydrolases | 1 | 2014 | 37 | 0.450 |
Why?
|
| Bronchoalveolar Lavage Fluid | 8 | 2018 | 151 | 0.440 |
Why?
|
| Fungal Proteins | 6 | 2023 | 132 | 0.430 |
Why?
|
| Signal Transduction | 10 | 2016 | 4637 | 0.430 |
Why?
|
| Immunity | 4 | 2025 | 194 | 0.430 |
Why?
|
| PPAR gamma | 1 | 2014 | 84 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 665 | 0.430 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 83 | 0.420 |
Why?
|
| Inhalation Exposure | 3 | 2021 | 37 | 0.420 |
Why?
|
| Metalloendopeptidases | 3 | 2002 | 101 | 0.420 |
Why?
|
| Biomarkers | 7 | 2022 | 3153 | 0.410 |
Why?
|
| Bronchial Hyperreactivity | 4 | 2021 | 38 | 0.410 |
Why?
|
| Proteomics | 5 | 2024 | 513 | 0.400 |
Why?
|
| Airway Obstruction | 4 | 2017 | 165 | 0.400 |
Why?
|
| Interleukins | 2 | 2013 | 121 | 0.390 |
Why?
|
| Serine Endopeptidases | 3 | 2021 | 184 | 0.390 |
Why?
|
| Fungi | 4 | 2018 | 70 | 0.380 |
Why?
|
| Interleukin-4 | 9 | 2018 | 142 | 0.380 |
Why?
|
| Cell Differentiation | 7 | 2024 | 1926 | 0.380 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 579 | 0.380 |
Why?
|
| Sinusitis | 4 | 2021 | 117 | 0.370 |
Why?
|
| Extracellular Matrix | 4 | 2018 | 241 | 0.370 |
Why?
|
| CD11b Antigen | 2 | 2023 | 36 | 0.370 |
Why?
|
| Female | 42 | 2024 | 67310 | 0.360 |
Why?
|
| Cells, Cultured | 11 | 2019 | 3040 | 0.350 |
Why?
|
| Interferon-gamma | 7 | 2023 | 510 | 0.350 |
Why?
|
| Gene Expression Regulation | 7 | 2014 | 2549 | 0.350 |
Why?
|
| Rhinovirus | 1 | 2010 | 59 | 0.340 |
Why?
|
| Down-Regulation | 3 | 2024 | 691 | 0.330 |
Why?
|
| Picornaviridae Infections | 1 | 2010 | 48 | 0.330 |
Why?
|
| Macrophages | 5 | 2022 | 641 | 0.330 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 115 | 0.330 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 20 | 0.320 |
Why?
|
| Immune Tolerance | 3 | 2019 | 146 | 0.320 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 21 | 0.310 |
Why?
|
| Rhinitis | 3 | 2021 | 38 | 0.310 |
Why?
|
| Immunoglobulin E | 5 | 2014 | 165 | 0.310 |
Why?
|
| Respiratory System | 7 | 2021 | 97 | 0.310 |
Why?
|
| Antifungal Agents | 3 | 2021 | 294 | 0.310 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 2 | 2021 | 19 | 0.310 |
Why?
|
| Transcriptome | 4 | 2021 | 1013 | 0.310 |
Why?
|
| Tretinoin | 1 | 2009 | 114 | 0.300 |
Why?
|
| Pneumococcal Infections | 1 | 2011 | 275 | 0.300 |
Why?
|
| Lung Diseases, Fungal | 2 | 2019 | 32 | 0.300 |
Why?
|
| Epithelial Cells | 5 | 2021 | 913 | 0.300 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 376 | 0.300 |
Why?
|
| Viral Proteins | 1 | 2010 | 347 | 0.300 |
Why?
|
| Pulmonary Aspergillosis | 2 | 2021 | 11 | 0.290 |
Why?
|
| Gene Expression Profiling | 6 | 2024 | 1788 | 0.290 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2008 | 16 | 0.290 |
Why?
|
| Aspergillus | 4 | 2019 | 27 | 0.290 |
Why?
|
| Respiratory Tract Infections | 2 | 2022 | 275 | 0.290 |
Why?
|
| Chemokines, CC | 3 | 2005 | 28 | 0.290 |
Why?
|
| Interleukin-13 | 8 | 2017 | 97 | 0.280 |
Why?
|
| Nicotine | 2 | 2019 | 144 | 0.280 |
Why?
|
| Lung Injury | 2 | 2020 | 122 | 0.270 |
Why?
|
| Candida albicans | 3 | 2023 | 76 | 0.270 |
Why?
|
| MicroRNAs | 3 | 2024 | 868 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 218 | 0.260 |
Why?
|
| Male | 32 | 2024 | 62009 | 0.260 |
Why?
|
| Complement C3a | 3 | 2015 | 19 | 0.260 |
Why?
|
| Anesthesia, General | 3 | 2015 | 118 | 0.260 |
Why?
|
| Coculture Techniques | 2 | 2019 | 230 | 0.260 |
Why?
|
| Homeostasis | 3 | 2019 | 710 | 0.250 |
Why?
|
| Middle Aged | 20 | 2024 | 27028 | 0.250 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3445 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 408 | 0.240 |
Why?
|
| Cell Movement | 7 | 2018 | 856 | 0.240 |
Why?
|
| Sarcoidosis | 2 | 2023 | 61 | 0.240 |
Why?
|
| Immunotherapy | 3 | 2021 | 683 | 0.240 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 207 | 0.240 |
Why?
|
| Aged | 18 | 2021 | 19960 | 0.240 |
Why?
|
| ErbB Receptors | 3 | 2020 | 287 | 0.240 |
Why?
|
| Image-Guided Biopsy | 2 | 2015 | 38 | 0.240 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2025 | 9 | 0.240 |
Why?
|
| Bronchi | 4 | 2021 | 102 | 0.240 |
Why?
|
| Microglia | 2 | 2023 | 105 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 255 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2015 | 65 | 0.230 |
Why?
|
| Conscious Sedation | 2 | 2015 | 57 | 0.230 |
Why?
|
| Spores, Fungal | 3 | 2021 | 15 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2006 | 176 | 0.230 |
Why?
|
| Case-Control Studies | 6 | 2019 | 3341 | 0.230 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 10 | 0.220 |
Why?
|
| Adult | 18 | 2024 | 29791 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 199 | 0.220 |
Why?
|
| Bronchitis, Chronic | 1 | 2024 | 18 | 0.220 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 30 | 0.210 |
Why?
|
| Immunophenotyping | 2 | 2018 | 327 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 256 | 0.210 |
Why?
|
| Body Fluids | 1 | 2024 | 48 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 1111 | 0.210 |
Why?
|
| Severity of Illness Index | 6 | 2022 | 2933 | 0.210 |
Why?
|
| Phenotype | 8 | 2024 | 4321 | 0.210 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 301 | 0.210 |
Why?
|
| Lymph Nodes | 2 | 2015 | 380 | 0.210 |
Why?
|
| Neutrophils | 2 | 2019 | 383 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2019 | 2393 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2024 | 130 | 0.200 |
Why?
|
| Veterans | 2 | 2024 | 1722 | 0.200 |
Why?
|
| Collagenases | 2 | 2001 | 18 | 0.200 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 2426 | 0.190 |
Why?
|
| Carbon | 1 | 2022 | 92 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 3456 | 0.190 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2022 | 28 | 0.190 |
Why?
|
| Candidiasis | 2 | 2021 | 128 | 0.190 |
Why?
|
| Particulate Matter | 1 | 2022 | 71 | 0.190 |
Why?
|
| Disintegrins | 1 | 2002 | 13 | 0.190 |
Why?
|
| Endopeptidases | 1 | 2002 | 116 | 0.190 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 502 | 0.190 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2021 | 4 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 515 | 0.190 |
Why?
|
| Blood | 1 | 2021 | 100 | 0.180 |
Why?
|
| Blood Chemical Analysis | 1 | 2021 | 81 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 1713 | 0.180 |
Why?
|
| Heterografts | 1 | 2021 | 179 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2002 | 105 | 0.170 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 21 | 0.170 |
Why?
|
| Furin | 1 | 2020 | 7 | 0.170 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2020 | 17 | 0.170 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 386 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 154 | 0.170 |
Why?
|
| Smoking Cessation | 1 | 2022 | 199 | 0.170 |
Why?
|
| Antigens, Fungal | 4 | 2014 | 34 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 321 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 502 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 206 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2022 | 370 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 54 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2023 | 511 | 0.170 |
Why?
|
| Antibodies, Fungal | 2 | 2014 | 13 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 302 | 0.160 |
Why?
|
| Threonine | 1 | 2019 | 61 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2025 | 832 | 0.160 |
Why?
|
| Leishmania major | 4 | 2013 | 28 | 0.160 |
Why?
|
| Solvents | 1 | 2019 | 44 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 127 | 0.160 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2020 | 101 | 0.160 |
Why?
|
| Dust | 3 | 2024 | 19 | 0.160 |
Why?
|
| Proline | 1 | 2019 | 79 | 0.160 |
Why?
|
| Leukocyte Elastase | 2 | 2019 | 19 | 0.160 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2019 | 14 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 8 | 2013 | 1006 | 0.160 |
Why?
|
| Mucus | 3 | 2018 | 37 | 0.160 |
Why?
|
| Phospholipids | 1 | 2019 | 105 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 104 | 0.160 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 137 | 0.160 |
Why?
|
| Inflammation Mediators | 3 | 2022 | 249 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 329 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2021 | 329 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2015 | 832 | 0.150 |
Why?
|
| Cerebrum | 1 | 2019 | 37 | 0.150 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 531 | 0.150 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 44 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2023 | 375 | 0.150 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2018 | 33 | 0.150 |
Why?
|
| Neoplasms | 3 | 2021 | 2805 | 0.150 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1997 | 27 | 0.150 |
Why?
|
| Glycine | 1 | 2019 | 168 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1558 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 504 | 0.150 |
Why?
|
| Candidemia | 1 | 2019 | 40 | 0.150 |
Why?
|
| Aspergillus oryzae | 3 | 2013 | 8 | 0.150 |
Why?
|
| Peptide Fragments | 3 | 2019 | 783 | 0.150 |
Why?
|
| Chemokine CXCL10 | 2 | 2011 | 53 | 0.150 |
Why?
|
| Cell Size | 1 | 1998 | 85 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 375 | 0.140 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 367 | 0.140 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 381 | 0.140 |
Why?
|
| Smad4 Protein | 1 | 2018 | 57 | 0.140 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2017 | 8 | 0.140 |
Why?
|
| Prognosis | 6 | 2022 | 4731 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 2 | 2015 | 35 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 3 | 2013 | 48 | 0.140 |
Why?
|
| Larynx | 1 | 2018 | 72 | 0.140 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 177 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 124 | 0.140 |
Why?
|
| Nasal Polyps | 2 | 2014 | 25 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 1985 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1725 | 0.140 |
Why?
|
| Mutagens | 1 | 2017 | 83 | 0.140 |
Why?
|
| Arginine | 1 | 2019 | 336 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 1998 | 150 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2018 | 71 | 0.140 |
Why?
|
| Cell Line | 2 | 2019 | 2735 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 148 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1291 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2019 | 746 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2018 | 89 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 3 | 2011 | 1135 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Goblet Cells | 1 | 2017 | 105 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2014 | 61 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2019 | 230 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 1038 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 151 | 0.130 |
Why?
|
| Smokers | 3 | 2022 | 40 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 260 | 0.130 |
Why?
|
| Phagocytosis | 2 | 2011 | 172 | 0.130 |
Why?
|
| Peptides | 1 | 2019 | 820 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2019 | 434 | 0.130 |
Why?
|
| Chemokines | 2 | 2014 | 134 | 0.120 |
Why?
|
| Peptidomimetics | 1 | 2015 | 12 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1129 | 0.120 |
Why?
|
| CD11a Antigen | 2 | 2013 | 12 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 467 | 0.120 |
Why?
|
| Phagocytes | 1 | 2015 | 23 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 34 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 183 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2002 | 631 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2018 | 611 | 0.120 |
Why?
|
| Immunologic Memory | 2 | 2014 | 194 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 711 | 0.120 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 63 | 0.120 |
Why?
|
| Autocrine Communication | 1 | 2014 | 28 | 0.120 |
Why?
|
| Intestines | 1 | 2019 | 580 | 0.120 |
Why?
|
| Complement C3 | 1 | 2014 | 49 | 0.120 |
Why?
|
| Complement Activation | 1 | 2014 | 52 | 0.110 |
Why?
|
| Leukotrienes | 1 | 2014 | 7 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 256 | 0.110 |
Why?
|
| Paracrine Communication | 1 | 2014 | 73 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2015 | 1019 | 0.110 |
Why?
|
| Eosinophils | 4 | 2021 | 120 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 113 | 0.110 |
Why?
|
| DNA Damage | 1 | 2017 | 518 | 0.110 |
Why?
|
| Ovalbumin | 3 | 2005 | 319 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 3 | 2021 | 383 | 0.110 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 35 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2017 | 1160 | 0.110 |
Why?
|
| Proteolysis | 1 | 2014 | 171 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 362 | 0.110 |
Why?
|
| Inflammasomes | 1 | 2015 | 153 | 0.110 |
Why?
|
| Immunity, Mucosal | 2 | 2011 | 87 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 154 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 343 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1274 | 0.110 |
Why?
|
| Chemokine CCL7 | 2 | 2004 | 7 | 0.110 |
Why?
|
| Chemokine CCL17 | 2 | 2004 | 9 | 0.110 |
Why?
|
| Monocyte Chemoattractant Proteins | 2 | 2004 | 8 | 0.110 |
Why?
|
| Chemokine CCL11 | 2 | 2004 | 12 | 0.100 |
Why?
|
| Kidney | 1 | 2020 | 1361 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1072 | 0.100 |
Why?
|
| Tracheitis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Mycosis Fungoides | 1 | 2012 | 14 | 0.100 |
Why?
|
| Bronchitis | 1 | 2012 | 34 | 0.100 |
Why?
|
| Chemotaxis | 2 | 2003 | 60 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 530 | 0.100 |
Why?
|
| Status Asthmaticus | 1 | 2012 | 20 | 0.100 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2010 | 22 | 0.100 |
Why?
|
| NF-kappa B | 4 | 2019 | 469 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2022 | 6175 | 0.100 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Fibroblasts | 3 | 2002 | 888 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2004 | 362 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1341 | 0.090 |
Why?
|
| Dipeptides | 2 | 2002 | 59 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 1512 | 0.090 |
Why?
|
| Pyruvic Acid | 1 | 2011 | 38 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2020 | 874 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 59 | 0.090 |
Why?
|
| Calgranulin B | 2 | 2008 | 9 | 0.090 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 2008 | 10 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 58 | 0.090 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 663 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Lectins | 2 | 2008 | 55 | 0.090 |
Why?
|
| Forecasting | 2 | 2005 | 358 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1038 | 0.090 |
Why?
|
| Virus Replication | 3 | 2021 | 613 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 402 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2017 | 1069 | 0.090 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 44 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2106 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6645 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 1536 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1299 | 0.080 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2012 | 310 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 2 | 2023 | 215 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2001 | 142 | 0.080 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 481 | 0.080 |
Why?
|
| Retinal Dehydrogenase | 1 | 2009 | 11 | 0.080 |
Why?
|
| Aspergillus fumigatus | 3 | 2005 | 42 | 0.080 |
Why?
|
| Bronchoconstriction | 2 | 2021 | 17 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2024 | 223 | 0.080 |
Why?
|
| Receptor, Adenosine A3 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 14 | 0.070 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 164 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2021 | 1204 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 344 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2008 | 36 | 0.070 |
Why?
|
| Integrins | 1 | 2008 | 98 | 0.070 |
Why?
|
| Tyrosine | 1 | 2008 | 154 | 0.070 |
Why?
|
| Proteins | 2 | 2011 | 1043 | 0.070 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 114 | 0.070 |
Why?
|
| Glucose | 1 | 2011 | 881 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2007 | 116 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 1716 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2021 | 2818 | 0.070 |
Why?
|
| Models, Biological | 4 | 2010 | 1470 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 294 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 171 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2006 | 1551 | 0.060 |
Why?
|
| Arylsulfonates | 1 | 2006 | 3 | 0.060 |
Why?
|
| Sulfonium Compounds | 1 | 2006 | 4 | 0.060 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 15 | 0.060 |
Why?
|
| Relaxin | 1 | 2006 | 15 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2011 | 771 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2006 | 43 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2006 | 27 | 0.060 |
Why?
|
| Omalizumab | 1 | 2006 | 34 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 119 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 113 | 0.060 |
Why?
|
| Fibronectins | 2 | 1996 | 110 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 2194 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5199 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 1277 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 143 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2007 | 271 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 88 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3203 | 0.060 |
Why?
|
| Macrophage Activation | 2 | 2016 | 67 | 0.060 |
Why?
|
| Desmosomes | 1 | 2004 | 7 | 0.060 |
Why?
|
| Proteome | 1 | 2006 | 257 | 0.060 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 21 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1102 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 99 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 38 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 45 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 37 | 0.060 |
Why?
|
| Spirometry | 1 | 2024 | 73 | 0.060 |
Why?
|
| Epidermis | 1 | 2004 | 63 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 370 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2005 | 796 | 0.060 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2025 | 114 | 0.060 |
Why?
|
| Gases | 1 | 2024 | 17 | 0.060 |
Why?
|
| CD18 Antigens | 1 | 2003 | 51 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 298 | 0.050 |
Why?
|
| Rabbits | 3 | 2001 | 719 | 0.050 |
Why?
|
| Ambrosia | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 170 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 414 | 0.050 |
Why?
|
| Leukocytes | 1 | 2004 | 213 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 155 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2003 | 47 | 0.050 |
Why?
|
| Pollen | 1 | 2002 | 46 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 117 | 0.050 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2002 | 3 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Splenomegaly | 1 | 2022 | 33 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 127 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 75 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 35 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 121 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 132 | 0.050 |
Why?
|
| Yersinia | 1 | 2001 | 5 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2022 | 173 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2012 | 240 | 0.050 |
Why?
|
| Synovial Membrane | 1 | 2001 | 27 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 114 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2002 | 154 | 0.050 |
Why?
|
| Computers | 1 | 2021 | 71 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 96 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 67 | 0.050 |
Why?
|
| Adolescent | 1 | 2019 | 19531 | 0.050 |
Why?
|
| Adhesins, Bacterial | 1 | 2001 | 75 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 46 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 10372 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2002 | 120 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2002 | 208 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 260 | 0.040 |
Why?
|
| Aspirin | 1 | 2002 | 223 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2013 | 803 | 0.040 |
Why?
|
| Monocytes | 1 | 2023 | 347 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2021 | 93 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2020 | 43 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 395 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 670 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 408 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 133 | 0.040 |
Why?
|
| American Heart Association | 1 | 2022 | 323 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 305 | 0.040 |
Why?
|
| Research Report | 1 | 2020 | 77 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 10 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 83 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 538 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1026 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 16514 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 119 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 683 | 0.040 |
Why?
|
| Protein Binding | 2 | 2019 | 1749 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 782 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 169 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 108 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 177 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1029 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 77 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 477 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 369 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2019 | 166 | 0.040 |
Why?
|
| Receptors, Fibronectin | 1 | 1998 | 8 | 0.040 |
Why?
|
| Cytochalasin D | 1 | 1998 | 11 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 173 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1998 | 24 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 18 | 0.040 |
Why?
|
| rac GTP-Binding Proteins | 1 | 1998 | 26 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 918 | 0.040 |
Why?
|
| Free Radicals | 1 | 1998 | 37 | 0.040 |
Why?
|
| Pleura | 1 | 2018 | 27 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 231 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2019 | 128 | 0.040 |
Why?
|
| Chemical Warfare | 1 | 2017 | 1 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1611 | 0.040 |
Why?
|
| Plethysmography | 1 | 2018 | 35 | 0.040 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 5 | 0.040 |
Why?
|
| Mustard Gas | 1 | 2017 | 5 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2017 | 21 | 0.040 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 497 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 117 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 19 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2017 | 19 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 477 | 0.040 |
Why?
|
| Exons | 1 | 2020 | 807 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 236 | 0.040 |
Why?
|
| Amino Acids | 1 | 2020 | 669 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1996 | 1261 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 251 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 106 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 486 | 0.030 |
Why?
|
| Azacitidine | 1 | 2017 | 53 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 2 | 2010 | 14 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 691 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2018 | 176 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 69 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 80 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 77 | 0.030 |
Why?
|
| United States | 2 | 2024 | 10988 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 158 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 4873 | 0.030 |
Why?
|
| Apoptosis | 1 | 2004 | 1835 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 244 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1998 | 382 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 50 | 0.030 |
Why?
|
| Clodronic Acid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cetuximab | 1 | 2016 | 12 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 13 | 0.030 |
Why?
|
| Metaplasia | 1 | 2017 | 214 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 459 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 278 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 68 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 258 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 46 | 0.030 |
Why?
|
| Exercise | 1 | 2002 | 828 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 838 | 0.030 |
Why?
|
| Cell Migration Inhibition | 2 | 2006 | 10 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1325 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 9 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1997 | 171 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1515 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 808 | 0.030 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 13 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 900 | 0.030 |
Why?
|
| Astrocytes | 1 | 2019 | 257 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Arrestins | 1 | 2015 | 29 | 0.030 |
Why?
|
| Genotype | 1 | 2002 | 2593 | 0.030 |
Why?
|
| Formoterol Fumarate | 1 | 2015 | 31 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 1110 | 0.030 |
Why?
|
| Propanolamines | 1 | 2015 | 32 | 0.030 |
Why?
|
| Carbazoles | 1 | 2015 | 33 | 0.030 |
Why?
|
| Albuterol | 1 | 2015 | 52 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 87 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 108 | 0.030 |
Why?
|
| Integrin beta1 | 2 | 2008 | 56 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 306 | 0.030 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 5 | 0.030 |
Why?
|
| Seawater | 1 | 1994 | 12 | 0.030 |
Why?
|
| Blood-Air Barrier | 1 | 1994 | 4 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 295 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 115 | 0.030 |
Why?
|
| Child | 3 | 2023 | 24740 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 80 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3715 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 121 | 0.030 |
Why?
|
| Aquaporins | 1 | 1994 | 18 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2014 | 43 | 0.030 |
Why?
|
| Body Water | 1 | 1994 | 89 | 0.030 |
Why?
|
| Mercury | 1 | 1994 | 29 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1994 | 122 | 0.030 |
Why?
|
| Rats | 3 | 1996 | 3762 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1800 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 367 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 427 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2013 | 90 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2019 | 531 | 0.030 |
Why?
|
| Ion Channels | 1 | 1994 | 192 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 328 | 0.030 |
Why?
|
| Immunization | 1 | 2014 | 308 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 179 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 348 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12379 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 559 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 743 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 544 | 0.020 |
Why?
|
| Ataxins | 1 | 2011 | 114 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2011 | 54 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 2719 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2011 | 21 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 257 | 0.020 |
Why?
|
| Organogenesis | 1 | 2011 | 80 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 154 | 0.020 |
Why?
|
| Ataxin-1 | 1 | 2011 | 162 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1560 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 363 | 0.020 |
Why?
|
| Obesity | 1 | 2002 | 2276 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 32 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 278 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 3901 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1399 | 0.020 |
Why?
|
| Thy-1 Antigens | 1 | 2010 | 22 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 677 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2010 | 45 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 67 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2069 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 820 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 554 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2009 | 43 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 829 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2011 | 301 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 39 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 51 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 560 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3459 | 0.020 |
Why?
|
| Bleomycin | 1 | 2008 | 153 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 129 | 0.020 |
Why?
|
| Joints | 1 | 2007 | 23 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2006 | 5 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 371 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 310 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 55 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2006 | 46 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 161 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 653 | 0.020 |
Why?
|
| Edema | 1 | 2007 | 137 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2006 | 294 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 5956 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2006 | 50 | 0.020 |
Why?
|
| Syndecans | 1 | 2005 | 4 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1997 | 3078 | 0.010 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2005 | 16 | 0.010 |
Why?
|
| Craniofacial Abnormalities | 1 | 2007 | 242 | 0.010 |
Why?
|
| Calcium | 1 | 2010 | 1111 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 133 | 0.010 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2004 | 6 | 0.010 |
Why?
|
| Bone Density | 1 | 2007 | 324 | 0.010 |
Why?
|
| Epithelium | 2 | 1996 | 362 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 276 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2004 | 151 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 659 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 765 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 285 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 1014 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 1024 | 0.010 |
Why?
|
| Fetus | 1 | 2006 | 590 | 0.010 |
Why?
|
| Munc18 Proteins | 1 | 2002 | 20 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2001 | 46 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 290 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 3118 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1997 | 22 | 0.010 |
Why?
|
| Vinculin | 1 | 1996 | 5 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1996 | 22 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1996 | 423 | 0.010 |
Why?
|
| Time Factors | 2 | 1996 | 6334 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 762 | 0.010 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1994 | 2 | 0.010 |
Why?
|
| Extravascular Lung Water | 1 | 1994 | 2 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1994 | 30 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1994 | 74 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 176 | 0.010 |
Why?
|
| Aquaporin 1 | 1 | 1994 | 8 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 1327 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 266 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 220 | 0.010 |
Why?
|
| Biological Transport | 1 | 1994 | 353 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1994 | 845 | 0.010 |
Why?
|